ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

Core Viewpoint - ZyVersa Therapeutics is advancing its Inflammasome ASC Inhibitor IC 100, which has shown promise in treating oxygen-induced retinopathy (ROP) in preclinical models, potentially addressing a significant cause of childhood blindness [2][3]. Group 1: Research Findings - A recent publication highlights the role of inflammasome ASC and ASC specks in oxygen-induced retinopathy, demonstrating that IC 100 can alleviate retinal structural and functional impairments [2]. - In mouse models, IC 100 significantly reduced the expression of inflammasome-related molecules and inflammatory cytokines, leading to decreased retinal inflammation and dysfunction [2][3]. - The treatment with IC 100 resulted in structural and functional improvements in the retina, correlating with the correction of gene pathways associated with eye development and inflammation [2]. Group 2: Company Overview - ZyVersa Therapeutics is a clinical stage biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a total accessible market exceeding $100 billion [5]. - The lead indication for IC 100 is obesity and its associated metabolic complications, with additional indications including early Alzheimer's disease, multiple sclerosis, and traumatic brain injury [3][5]. - The company is well-positioned in the inflammasome space with its differentiated monoclonal antibody, IC 100, and is also developing VAR 200 for focal segmental glomerulosclerosis [5].